Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1987 Apr;31(4):632–634. doi: 10.1128/aac.31.4.632

Synergism of the combinations of imipenem plus ciprofloxacin and imipenem plus amikacin against Pseudomonas aeruginosa and other bacterial pathogens.

C I Bustamante, G L Drusano, R C Wharton, J C Wade
PMCID: PMC174794  PMID: 3111357

Abstract

The combinations of imipenem plus ciprofloxacin and imipenem plus amikacin were investigated for their activity against Pseudomonas aeruginosa and other bacterial pathogens. For imipenem-susceptible P. aeruginosa, synergy of imipenem plus ciprofloxacin and imipenem plus amikacin was observed against 36 and 45% of the strains, respectively. The incidence of synergy against imipenem-resistant isolates of P. aeruginosa was 10% for both combinations. Antagonism was not observed with either combination.

Full text

PDF
632

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Benbrook D. M., Miller R. V. Effects of norfloxacin on DNA metabolism in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1986 Jan;29(1):1–6. doi: 10.1128/aac.29.1.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bertram M. A., Young L. S. Imipenem antagonism of the in vitro activity of piperacillin against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1984 Aug;26(2):272–274. doi: 10.1128/aac.26.2.272. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Chalkley L. J., Koornhof H. J. Antimicrobial activity of ciprofloxacin against Pseudomonas aeruginosa, Escherichia coli, and Staphylococcus aureus determined by the killing curve method: antibiotic comparisons and synergistic interactions. Antimicrob Agents Chemother. 1985 Aug;28(2):331–342. doi: 10.1128/aac.28.2.331. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Chin N. X., Jules K., Neu H. C. Synergy of ciprofloxacin and azlocillin in vitro and in a neutropenic mouse model of infection. Eur J Clin Microbiol. 1986 Feb;5(1):23–28. doi: 10.1007/BF02013456. [DOI] [PubMed] [Google Scholar]
  5. Chin N. X., Neu H. C. Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria. Antimicrob Agents Chemother. 1984 Mar;25(3):319–326. doi: 10.1128/aac.25.3.319. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. De Jongh C. A., Joshi J. H., Newman K. A., Moody M. R., Wharton R., Standiford H. C., Schimpff S. C. Antibiotic synergism and response in gram-negative bacteremia in granulocytopenic cancer patients. Am J Med. 1986 May 30;80(5C):96–100. [PubMed] [Google Scholar]
  7. De Jongh C. A., Joshi J. H., Thompson B. W., Newman K. A., Finley R. S., Moody M. R., Salvatore P. C., Tenney J. H., Drusano G. L., Schimpff S. C. A double beta-lactam combination versus an aminoglycoside-containing regimen as empiric antibiotic therapy for febrile granulocytopenic cancer patients. Am J Med. 1986 May 30;80(5C):101–111. [PubMed] [Google Scholar]
  8. Díez Enciso M., Mateos Lindemann M., Gutiérrez Altés A. In vitro evaluation of N-formimidoyl thienamycin (MK0787) combined with amikacin against gram-negative bacilli and Staphylococcus aureus. Antimicrob Agents Chemother. 1982 Dec;22(6):1064–1066. doi: 10.1128/aac.22.6.1064. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Eliopoulos G. M., Gardella A., Moellering R. C., Jr In vitro activity of ciprofloxacin, a new carboxyquinoline antimicrobial agent. Antimicrob Agents Chemother. 1984 Mar;25(3):331–335. doi: 10.1128/aac.25.3.331. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Haller I. Comprehensive evaluation of ciprofloxacin-aminoglycoside combinations against Enterobacteriaceae and Pseudomonas aeruginosa strains. Antimicrob Agents Chemother. 1985 Nov;28(5):663–666. doi: 10.1128/aac.28.5.663. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Hooton T. M., Blair A. D., Turck M., Counts G. W. Synergism at clinically attainable concentrations of aminoglycoside and beta-lactam antibiotics. Antimicrob Agents Chemother. 1984 Oct;26(4):535–538. doi: 10.1128/aac.26.4.535. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Klastersky J., Zinner S. H. Synergistic combinations of antibiotics in gram-negative bacillary infections. Rev Infect Dis. 1982 Mar-Apr;4(2):294–301. doi: 10.1093/clinids/4.2.294. [DOI] [PubMed] [Google Scholar]
  13. Pizzo P. A., Hathorn J. W., Hiemenz J., Browne M., Commers J., Cotton D., Gress J., Longo D., Marshall D., McKnight J. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med. 1986 Aug 28;315(9):552–558. doi: 10.1056/NEJM198608283150905. [DOI] [PubMed] [Google Scholar]
  14. Sanders C. C., Sanders W. E., Jr, Goering R. V. In vitro antagonism of beta-lactam antibiotics by cefoxitin. Antimicrob Agents Chemother. 1982 Jun;21(6):968–975. doi: 10.1128/aac.21.6.968. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Tausk F., Evans M. E., Patterson L. S., Federspiel C. F., Stratton C. W. Imipenem-induced resistance to antipseudomonal beta-lactams in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1985 Jul;28(1):41–45. doi: 10.1128/aac.28.1.41. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Van der Auwera P., Klastersky J., Lagast H., Husson M. Serum bactericidal activity and killing rate for volunteers receiving imipenem, imipenem plus amikacin, and ceftazidime plus amikacin against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1986 Jul;30(1):122–126. doi: 10.1128/aac.30.1.122. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Wade J. C., Standiford H. C., Drusano G. L., Johnson D. E., Moody M. R., Bustamante C. I., Joshi J. H., deJongh C., Schimpff S. C. Potential of imipenem as single-agent empiric antibiotic therapy of febrile neutropenic patients with cancer. Am J Med. 1985 Jun 7;78(6A):62–72. doi: 10.1016/0002-9343(85)90103-2. [DOI] [PubMed] [Google Scholar]
  18. Winston D. J., Barnes R. C., Ho W. G., Young L. S., Champlin R. E., Gale R. P. Moxalactam plus piperacillin versus moxalactam plus amikacin in febrile granulocytopenic patients. Am J Med. 1984 Sep;77(3):442–450. doi: 10.1016/0002-9343(84)90100-1. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES